SRT Sartorius AG

After yesterday�s meeting, the Board of Directors announced the election of Maik W. Jornitz as Chair-Elect (Vice Chairman) of the Board of the Parenteral Drug Association (PDA). The Group Vice President, Marketing Filtration and Fermentation, at Sartorius Stedim Biotech (FWB:SRT), has been an active member of the PDA for close to 15 years, holding multiple functions. Before becoming Chair-Elect, he was Treasurer and Chair of the 2008 Annual Meeting as well as a Task Forces member, including his direct involvement in Technical Report 26 on Liquid Sterilizing Filtration. The PDA is a key global pharmaceutical association with over 10,000 members. �The PDA is the most prominent and effective platform of scientific communication and discussion between members of the biopharmaceutical and pharmaceutical industry, academia and regulatory institutions,� said Jornitz. �It is an honor to be part of PDA�s vital function in supporting regulators and the biopharmaceutical industry as well as shaping the newest developments in this industry. I am very happy to join this senior level and distinguished Board of Directors.� John Shabushnig was elected Chair of the PDA Board. Furthermore, representatives of the pharmaceutical groups Genentech, Amgen, Pfizer, Baxter and Eli Lilly, among others, belong to this Board. Maik W. Jornitz has been with Sartorius for over 20 years and is an established filtration technology expert with a focus on sterilizing filtration, process validation and integrity testing. Jornitz authored and co-authored numerous scientific books, and regularly publishes technical papers. He holds multiple patents for integrity test methods and filter housing designs. Jornitz is a faculty member of PDA�s Training & Research Institute. Current image file: Maik W. Jornitz, Group Vice President Marketing & Product Management Filtration/Fermentation Technologies at Sartorius Stedim Biotech. http://www.sartorius-stedim.com/media/content/press/support/Jornit z.jpg (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.) A profile of Sartorius Stedim Biotech Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. For next generation processes, Sartorius Stedim Biotech focuses on single-use technologies and added-value services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of �Turning science into solutions.� Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and sales companies in Europe, North America and Asia, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D location is in Germany. The company employs over 2,200 people, and in 2006 earned pro forma sales revenue of more than 360 million euros. This is a translation of the original German-language press release. Sartorius shall not assume any liability for the correctness of this translation. The original German press release is the legally binding version. Furthermore, Sartorius reserves the right not to be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected. http://www.sartorius-stedim.com